Treatment of rats with monocrotaline (MCT) leads to pulmonary hypertension, right ventricular (RV) hypertrophy, and finally to RV heart failure. This is associated with characteristic changes in right ventricular beta-adrenoceptors (beta-AR), neuronal noradrenaline transporter (NAT) density and activity (uptake(1)), and G protein-coupled receptor kinase (GRK) activity. This study aimed to find out factors that determine beta-AR, uptake(1), and GRK changes. Thus, 6-week-old rats were treated with 50 mg/kg MCT subcutaneous or 0.9% saline. Within 13 to 19 days after MCT application (group A), RV weight (222 +/- 6 versus 147 +/- 5 mg) and RV/left ventricular (LV) weight ratio (0.42 +/- 0.01 versus 0.29 +/- 0.01) were significantly increased, whereas plasma noradrenaline, RV beta-AR density, RV NAT density and activity, and RV GRK activity were not significantly altered. Twenty-one to twenty-eight days after MCT (group B), however, not only RV weight (316 +/- 4 versus 149 +/- 2 mg) and RV/LV weight ratio (0.61 +/- 0.01 versus 0.3 +/- 0.01) were markedly increased but also plasma noradrenaline (645 +/- 63 versus 278 +/- 18 pg/mL); now, RV beta-AR density (13.4 +/- 1.3 versus 26.5 +/- 1.1 fmol/mg protein), RV NAT density (50.9 +/- 11.3 versus 79.6 +/- 2.9 fmol/mg protein), and RV NAT activity (65.4 +/-7.4 versus 111.8 +/- 15.9 pmol [H-3]-NA/mg tissue slices/15 min) were significantly decreased and RV-membrane GRK activity (100 +/- 15 versus 67 +/- 6 [P-32]-rhodopsin in cpm) significantly increased. LV parameters of MCT-treated rats were only marginally different from control LV. We conclude that in MCT-treated rats ventricular hypertrophy per se is not sufficient to cause characteristic alterations in the myocardial beta-AR system often seen in heart failure, only if ventricular hypertrophy is associated with neurohumoral activation beta-ARs are downregulated and GRK activity is increased.